Keros Therapeutics, Inc.Keros Therapeutics, Inc.Keros Therapeutics, Inc.

Keros Therapeutics, Inc.

No trades
See on Supercharts

KROS fundamentals

Keros Therapeutics, Inc. key financial stats and ratios

KROS price-to-sales ratio is 2.33. The company has an Enterprise Value to EBITDA ratio of -68.55. As of 2024 they employed 169 people.

Statistics
Q1 '19
Q2 '19
Q3 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Price to earnings ratio
Price to cash flow ratio
Currency: USD
Q1 '19
Q2 '19
Q3 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Current
Key stats
Valuation ratios
Profitability ratios
Liquidity ratios
Solvency ratios
Per share metrics